Valutazione del libro
Parametri
- 288pagine
- 11 ore di lettura
Maggiori informazioni sul libro
This book reveals the little-known story of how a biotechnology company developed a groundbreaking cancer drug and how its core team, denied their profits, achieved success again. A veteran financial journalist narrates the saga of two major cancer drugs that became monumental Wall Street investments. In the multibillion-dollar biotech industry, where pharmaceutical companies, the government, hedge funds, and venture capitalists invest heavily, discovering a single molecule can halt cancer and enrich its discoverers. The narrative follows a small team at a California biotech start-up that identified a rare molecule, a BTK inhibitor, effective against a severe type of leukemia. As patients begin to recover, the team realizes they have made a significant breakthrough. The story unfolds with genius, emotion, and drama, featuring vivid characters navigating corporate intrigue and ethical dilemmas. The author immerses readers in the biotech start-up boom, highlighting the scientists, doctors, and investors risking everything for life-saving treatments, as well as patients facing life-or-death stakes. This gripping nonfiction work illustrates the challenges of bringing new drugs to market, their high costs, and the influence of profit-driven venture capitalists on the future of medicine.
Acquisto del libro
For Blood and Money: Billionaires, Biotech, and the Quest for a Blockbuster Drug, Vardi Nathan
- Lingua
- Pubblicato
- 2023
- product-detail.submit-box.info.binding
- (Copertina rigida)
Metodi di pagamento
Qui potrebbe esserci la tua recensione.
- Lingua
- Inglese
- Autori
- Vardi Nathan
- Editore
- W W NORTON & CO
- Pubblicato
- 2023
- Formato
- Copertina rigida
- Pagine
- 288
- ISBN10
- 0393540952
- ISBN13
- 9780393540956
- Serie
- Tag
- Saggistica, Tema stórico, Commercio, Business & Management, Tecnologia & Ingegneria, Salute & Medicina, Storia, Scienza e Matematica, Scienze Naturali, Medicina, Biologia, Scienza, Tecnologia, Medicina, Marketing & Vendite, Regali per gli uomini
- Valutazione
- 4,25 su 5
- Descrizione
- This book reveals the little-known story of how a biotechnology company developed a groundbreaking cancer drug and how its core team, denied their profits, achieved success again. A veteran financial journalist narrates the saga of two major cancer drugs that became monumental Wall Street investments. In the multibillion-dollar biotech industry, where pharmaceutical companies, the government, hedge funds, and venture capitalists invest heavily, discovering a single molecule can halt cancer and enrich its discoverers. The narrative follows a small team at a California biotech start-up that identified a rare molecule, a BTK inhibitor, effective against a severe type of leukemia. As patients begin to recover, the team realizes they have made a significant breakthrough. The story unfolds with genius, emotion, and drama, featuring vivid characters navigating corporate intrigue and ethical dilemmas. The author immerses readers in the biotech start-up boom, highlighting the scientists, doctors, and investors risking everything for life-saving treatments, as well as patients facing life-or-death stakes. This gripping nonfiction work illustrates the challenges of bringing new drugs to market, their high costs, and the influence of profit-driven venture capitalists on the future of medicine.